Zimmer Biomet Holdings Stock Issuance Proceeds increased by 623.5% to $12.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 26.3%, from $16.70M to $12.30M. Over 4 years (FY 2021 to FY 2025), Stock Issuance Proceeds shows a downward trend with a -24.5% CAGR.
Higher proceeds often correlate with employee participation in stock-based compensation programs rather than external capital raising.
Cash inflows resulting from the issuance of common stock, typically through employee stock option exercises or equity co...
Standard for large-cap companies with significant equity-based compensation programs.
proceeds_from_stock_issuance| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $26.20M | $25.80M | $5.20M | $40.50M | $4.50M | $18.20M | $14.90M | $36.00M | $25.10M | $20.70M | $19.30M | $56.40M | $6.60M | $18.60M | $500.00K | $16.70M | $400.00K | $20.90M | $1.70M | $12.30M |
| QoQ Change | — | -1.5% | -79.8% | +678.8% | -88.9% | +304.4% | -18.1% | +141.6% | -30.3% | -17.5% | -6.8% | +192.2% | -88.3% | +181.8% | -97.3% | >999% | -97.6% | >999% | -91.9% | +623.5% |
| YoY Change | — | — | — | — | -82.8% | -29.5% | +186.5% | -11.1% | +457.8% | +13.7% | +29.5% | +56.7% | -73.7% | -10.1% | -97.4% | -70.4% | -93.9% | +12.4% | +240.0% | -26.3% |